The Global Insulin Pens Market to gain from rising prevalence of diabetes around the world. Fortune Business Insights recently announced a report, titled “Insulin Pens Market Size, Share and Global Trend by Product Type (Disposable, Reusable), By Application (Type 1 Diabetes, Type 2 Diabetes), By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Diabetes Clinics), Geography Forecast till 2026.”
The market is expected to witness high demand in North America owing to the increasing prevalence of diabetes in nations such as the U.S. and Canada. Additionally, rapid technological advancements in insulin pens in the region is likely to propel growth in the market.
Browse Complete Report:
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook and SWOT analysis:
- Braun Medical
- Eli Lilly and Company
- Novo Nordisk
- Owen Mumford Ltd
- Ypsomed AG
- Terumo Medical Corporation
- HTL-Strefa, Inc.
In addition to this, growth in Europe is expected to be commendable backed by the shifting consumer preference in favor of self-administering medicines rather than depending on hospitals and clinics. This is further expected to increase the growth rate of the global market. Besides this, Asia Pacific is expected to expand at a relatively higher CAGR owing to a large patient pool present in the region. Furthermore, innovative market penetration strategies used by key players in the region is anticipated to facilitate adoption of insulin pens.
“Key player are expected to raise awareness and promote self-use of insulin pens. This in turn is likely to facilitate the adoption of insulin pens among patients and enable growth in the global insulin pens market.” Said a lead analyst at Fortune Business Insights.
Get PDF Brochure of this Report:
Increasing Healthcare Expenditure to Drive Market
Increasing per capita income and increasing healthcare expenditure are some factors anticipated to drive the global market during the forecast period. Additionally, technological upgrades in the insulin pens is likely to propel adoption of pens.
For instance, Novo Nordisk A/S announced the launch of a Bluetooth connected smart insulin pen in 2018. The smart pen is enabled to record the dose of insulin and timely logs. The amount of pain is comparatively less to normal insulin pens.
On the contrary, high price of insulin pens and looming risk of administering wrong dose of insulin are some factors that may restrain the global insulin pens market.
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East and Africa (South Africa, GCC and Rest of Middle East and Africa)
By Distribution Channel:
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
- Diabetes Clinics
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
View Related Report:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune – 411045, Maharashtra, India.
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245